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Abstract Temozolomide (TMZ) is standard chemother-
apy for glioblastoma multiforme (GBM). Intratumoral
hypoxia is common in GBM and may be associated with
the development of TMZ resistance. Oxygen therapy has
previously been reported to potentiate the effect of che-
motherapy in cancer. In this study, we investigated whether
hyperoxia can enhance the TMZ-induced cytotoxicity of
human GBM cells, and whether and how it would resen-
sitize TMZ-resistant GBM cells to TMZ. TMZ-sensitive
human GBM cells (D54-S and U87-S) were treated with
TMZ to develop isogenic subclones of TMZ-resistant cells
(D54-R and U87-R). All cell lines were then exposed to
different oxygen levels (1, 21, 40, or 80 %), with or
without concomitant TMZ treatment, before assessment of
cell cytotoxicity and morphology. Cell death and survival
pathways elicited by TMZ and/or hyperoxia were eluci-
dated by western blotting. Our results showed that TMZ
sensitivity of both chemo-sensitive and resistant cells was
enhanced significantly under hyperoxia. At the cell line-
specific optimum oxygen concentration (D54-R, 80 %;
U87-R, 40 %), resistant cells had the same response to
TMZ as the parent chemosensitive cells under normoxia
via the caspase-dependent pathway. Both TMZ and
hyperoxia were associated with increased phosphorylation
of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in
D54-R cells, suggesting that Erk1/2 activity may be
involved in regulation of hyperoxia and TMZ-mediated
cell death. Overall, hyperoxia enhanced TMZ toxicity in
GBM cells by induction of apoptosis, possibly via MAPK-
related pathways. Induced hyperoxia is a potentially
promising approach for treatment of TMZ-resistant GBM.
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Abbreviation
GBM Glioblastoma multiforme
HBO Hyperbaric oxygen
IC50 Half-maximum inhibitory concentration
ROS Reactive oxygen species
SRB Sulforhodamine B
TMZ Temozolomide
Introduction
Glioblastoma multiforme (GBM) is a highly malignant
primary brain tumor characterized by rapid growth, inva-
siveness, early recurrence, and resistance to conventional
therapy. Overall prognosis is poor; median survival is
approximately 12 months [1]. The current regimen for
treatment of GBM after maximum surgical resection
includes concomitant chemo-radiation using temozolomide
(TMZ), followed by six cycles of adjuvant TMZ [2].
Although TMZ can significantly prolong survival, many
patients continue to suffer from recurrent disease, because
of de-novo or acquired drug resistance [3, 4]. The mech-
anism underlying TMZ resistance is incompletely under-
stood [5], and, because TMZ is now standard therapy and
forms the control arm in clinical trials of other novel
agents, understanding and overcoming TMZ resistance is
urgent, and is an active area of investigation [6].
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The biological effects of hyperoxia have been widely
studied for a variety of neurological conditions, for
example carbon monoxide poisoning, traumatic brain
injury, and ischemic stroke [7–9]. The potential beneficial
effects of hyperoxia have been attributed to increased
oxygenation within the plasma and brain tissues which can
potentially stabilize intracranial pressure, prevent blood–
brain barrier disruption, suppress neutrophil–endothelial
adhesion, and reduce edema [8, 10]. On the other hand,
hyperoxia may activate apoptosis by induction of reactive
oxygen species (ROS). Hyperoxia may also interfere with
expression of cytokines, growth factors, and transcription
factors whereby survival or cell-death pathways are
affected to different degrees [11]. Its therapeutic role,
therefore, remains controversial.
Intra-tumoral hypoxia is common in GBM, and hypoxic
cancer cells are known to be more resistant to radiation or
cytotoxic drugs [12, 13]. Conversely, hyperoxia has been
shown to potentiate the effect of these treatments by
enhancing chemocytotoxicity in vitro [14] and neovascu-
larization in vivo [15]. Although hyperoxia has previously
been described for control of tumor growth and progression
in glioma, its potential application as an adjunct to che-
motherapy has not been investigated [16, 17]. In this study
we investigated whether and how different concentrations
of environmental oxygen would affect TMZ toxicity in
chemosensitive and chemoresistant GBM cells. The
hypothesis was that hyperoxia would enhance the effect of
TMZ especially in TMZ-resistant GBM cells.
Materials and methods
TMZ-resistant cells and treatment
We have previously described the development of iso-
genic subclones of TMZ-resistant GBM cells by means of
chronic TMZ exposure [18]. Briefly, human GBM cell
lines, D54-MG (Duke University Medical Center, USA)
and U87-MG (American Type Culture Collection,
Manassas, VA, USA), were cultured in Dulbecco’s
modified Eagle’s medium (DMEM)/F12 (1:1) and mini-
mum essential medium (MEM)-a, respectively. These
were supplemented with 10 % heat inactivated fetal
bovine serum (Gibco; Invitrogen, Grand Island, NY,
USA). Parent TMZ-sensitive cells (designated D54-S and
U87-S) were initially exposed to 100 lM TMZ (Temodal;
Schering–Plough, Whitehouse Station, NJ, USA) for two
weeks and then continuously to the IC50 of TMZ for
12 months. The TMZ-resistant subclones (D54-R and
U87-R) so produced were isolated and maintained in low
dose (100 lM) TMZ.
Oxygen treatment
TMZ-sensitive (D54-S and U87-S) and resistant (D54-R
and U87-R) cells were exposed to different degrees of
oxygen saturation under normobaric conditions (hypoxia,
1 %; normoxia, 21 %; hyperoxia 40 or 80 %), with or
without concomitant TMZ for 72 h. Cells were then
examined for in-vitro chemosensitivity, apoptosis-related
and survival-related protein changes.
Clonogenic assay
Cells were seeded at a density of 500 cells/well on six-well
plates. After incubation for 24 h they were treated with
TMZ (250, 500, 1,000, or 2,000 lM) for 48 h. Cells
without TMZ challenge were used as control cells. Cells
were then rinsed with fresh medium and left to form col-
onies after incubation for 14 days. Colonies were then
stained with crystal violet (5 g/L; Sigma–Aldrich, Saint
Louis, MO, USA). Percentage inhibition was calculated as
the number of colonies formed under the treatment con-
ditions relative to the control. Error bars represented
standard deviations from three independent experiments
conducted in triplicate. **P \ 0.01 and *P \ 0.05, versus
control.
Cytotoxicity assay
Cytotoxicity was measured by sulforhodamine B (SRB)
assay (Sigma–Aldrich). Cells were seeded in 96-well plates
(5,000 cells/well) and cultured in the absence or presence
of TMZ (250, 500, 1,000, 2,000, and 3,000 lM) for 96 h.
Determination of cell density was based on cellular protein
content as measured by absorbance (OD) at 490 nm. The
percentages of viable cells relative to the controls (cells
without previous TMZ treatment) were calculated and
plotted. The IC50 values were calculated by derivation of
the best-fit line, by use of three independent experiments
performed in triplicate.
Western blot
Total protein lysates (30 lg) were separated by 12 % SDS-
PAGE using a Mini-Protean electrophoresis cell (Bio-Rad
Laboratories, Hercules, CA, USA), and then transferred to
a PVDF membrane (0.22 lm; Millipore, Bedford, MA,
USA) by use of a Mini Trans-Blot cell (Bio-Rad Labora-
tories). After blocking, the membrane was probed with one
of the following primary antibodies at 1:1,000 dilution for
1 h: rabbit monoclonal antibodies against caspase 3, bax,
bcl-2, total p44/42 MAP Kinase (Erk 1/2), and phosphor-
p44/42 MAP kinase (Erk1/2) (Thr202/Tyr204) (all
from Cell Signaling Technology, Danvers, MA, USA).
468 J Neurooncol (2012) 109:467–475
123
HRP-conjugated secondary antibodies at 1:10,000 were
then used for incubation for 1 h. Immunoreactivity signals
were amplified by use of the ECL Plus western blotting
detection system (GE Biosciences, Buckinghamshire, UK).
Results
TMZ-resistant GBM cells
After exposing the parent D54-S and U87-S cells to TMZ
for 10 months, isogenic TMZ-resistant subclones (D54-R
and U87-R) were developed. Clonogenic formation assays
were performed after TMZ re-challenge. Compared with
the resistant cell lines (D54-R and U87-R), reduced clo-
nogenic formation was observed for D54-S and U87-S
14 days after TMZ treatment (Fig. 1a). Colony formation
was significantly inhibited (P \ 0.05) in the TMZ-sensitive
cell lines upon further challenge with different concentra-
tions of TMZ (250 500, 1,000, and 2,000 lM) (Fig. 1b).
On the basis of the percentages of colonies formed relative
to the control, IC50 for D54-R and U87-R cells was
increased sixfold (IC50 = 2,861.6 lM; P \ 0.05) and
threefold (IC50 = 1,731.74 lM; P \ 0.05) compared with
the parent control cells (D54-S, IC50 = 480.8 lM and
U87-S, IC50 = 590.1 lM). The results indicated that we
had successfully generated two isogenic TMZ-resistant
GBM subclones.
Hyperoxia induced cell death synergistically with TMZ
Seeded cells were incubated for 72 h at three oxygen levels
(hypoxia, 1 %; normoxia, 21 %; and hyperoxia, 40 or
80 %) with or without concomitant TMZ. In the absence of
TMZ, survival of both chemosensitive (D54-S and U87-S)
and chemoresistant (D54-R and U87-R) cells increased
under hypoxia (1 %), and a mild decrease was observed
under cell type-dependent optimum hyperoxic conditions
(D54-80 % and U87-40 %) (Fig. 2). With concomitant
TMZ given at the IC50 for the parent cells, hyperoxia
caused a marked decrease in cell survival, especially for
the TMZ-resistant cells. These findings were suggestive of
a synergistic effect between hyperoxia and TMZ in
inducing cell death. Furthermore, under light microscopy,
cells cultured under hyperoxia had altered morphology
with increased pseudopod formation (Fig. 2).
Hyperoxia enhances chemosensitivity of TMZ-resistant
GBM cells
In-vitro chemosensitivity assay showed that cell survival
was affected by the ambient oxygen concentration. Fig-
ure 3a, b shows that hypoxia had a survival benefit for both
sensitive (D54-S and U87-S) and resistant (D54-R and
U87-R) cells against TMZ, whereas hyperoxia led to
growth inhibition. Figure 3c shows the corresponding IC50
values and their respective ratios compared with the IC50
Fig. 1 TMZ-resistant D54-R
and U87-R cells.
(a) Representative dishes from
clonogenic assay of the four
cells 14 days after TMZ
treatment. (b) Clonogenic
percentage survival of TMZ-
sensitive (D54-S and U87-S)
and TMZ-resistant (D54-R and
U87-R) cells after rechallenge
with TMZ. Each experiment
was repeated three times and
performed in triplicate.
Columns, mean results from
triplicate assay; bars, SD;
*P \ 0.05 and **P \ 0.01
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values under normoxia. Overall, IC50 were highest for both
TMZ-sensitive and TMZ-resistant cell lines under hypoxia.
Compared with cells under normoxia, the IC50 for D54-S
and D54-R cells increased 1.9-fold and 1.4-fold, respec-
tively, under hypoxia. Similarly, the IC50 for U87-S and
U87-R cells increased 1.4-fold and 1.1-fold, respectively.
Hyperoxia had the opposite effect, resulting in a rapid
reduction in cell growth. At 40 % hyperoxia, 1.3 and 2-fold
decreases in IC50 were observed for D54-S and U87-S
cells, respectively. Similar inhibitory effects were also
observed for D54-R and U87-R cells, for which 1.1 and
2.4-fold decreases, respectively, were observed.
This phenomenon of hyperoxia-induced growth inhibi-
tion was cell line-dependent (Fig. 3c). D54 cells were less
sensitive to 40 % oxygen than U87 cells, as was apparent
from the lower ratio compared with normoxia for both
sensitive and resistant cells. At 80 % hyperoxia, 1.8 and
1.9-fold decreases in IC50 were observed for D54-S and
D54-R cells, respectively, whereas most of the U87 cells
died (results not shown). Moreover, hyperoxia was found
to ameliorate TMZ resistance in both D54-R and U87-R
cells, with a decreases in IC50 from 759.95 lM (D54-R)
and 1708.99 lM (U87-R) under 21 % O2, to
393.56 lM (D54-R under 80 % O2) and 698.88 lM (U87-
R under 40 % O2), respectively. These were lower than that
for the parent cell lines under normoxic conditions. Our
findings indicate that the response of GBM to TMZ was
significantly affected by environmental oxygen saturation.
Hyperoxia may potentiate the anti-tumor effect of TMZ,
whereas hypoxia may reduce TMZ sensitivity.
Hyperoxia-induced cell death through caspase-
dependent pathways
We then examined if hyperoxia-induced cell death was
dependent on pro-apoptotic pathways. Mediators of
apoptosis were examined for their altered protein
expression under different treatment conditions. Treat-
ment with TMZ or exposure to hyperoxia alone was
associated with upregulation of the pro-apoptotic protein
Bax, and almost unaltered, if not reduced, expression of
the anti-apoptotic protein Bcl-2 (Fig. 4). These resulted
in an increased Bax:Bcl-2 ratio, hence cell death. The
most significant response was observed after combining
TMZ with hyperoxia, which resulted in an increase in
caspase 3 activity, known to be the ‘‘executioner’’ of
apoptosis. Our findings suggested that the synergistic
effects of TMZ and hyperoxia were at least partially
mediated via caspase-dependent apoptosis. Interestingly,
for D54-R and U87-R cells activation of apoptosis was of
similar extent after exposure to hyperoxia with or without
concomitant TMZ. The result suggested that hyperoxia
alone may be potent enough for attenuation of TMZ
resistance.
Hyperoxia activated the ERK p44/42 MAPK (Erk1/2)
signal-transduction pathway
Cellular stress, for example DNA damage, and oxidative
stress are known to activate cascades of protein kinases that
Fig. 2 Morphology changed after 72 h treatment at different oxygen saturation with or without concomitant TMZ. a D54, b U87 cells
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participate in signal transduction. The MAPK pathway is
one of these signaling pathways. We therefore investigated
whether activation of ERK1/2 was involved in GBM’s
responses to hyperoxia and TMZ. We immunoblotted the
total and phosphorylated forms of Erk1/2 proteins under
different treatment conditions (Fig. 5). We found upregu-
lation of phosphor-Erk1/2 protein in both the TMZ-sensi-
tive (D54-S and U87-S) and TMZ-resistant (D54-R and
U87-R) cells after hyperoxia or TMZ treatment, indicating
that both stressful stimuli could activate the Erk1/2 signal
transduction pathway. Moreover, Erk1/2 activity was
higher in D54-S and U87-S cells than in D54-R and U87-R
cells after 72 h, suggesting that TMZ-resistant GBM cells
may be less responsive to oxidative and DNA damage
stressors. We then investigated the effect of combined
hyperoxia–TMZ treatment. For both D54-S and U87-S
cells, phosphor-Erk1/2 expression increased in an oxygen-
dependent manner when coupled with TMZ treatment
(Fig. 5). The findings suggested the MAPK pathway may
be important in the hyperoxia-induced and TMZ-induced
signal transduction which mediates other death signaling
pathways.
Fig. 3 Survival curves for
a D54 and b U87 cells under
different oxygen saturation
conditions. c Alteration of TMZ
IC50 values and their respective
ratio to normoxia under
different oxygen saturation
conditions for TMZ-sensitive
(D54-S and U87-S) and TMZ-
resistant (D54-R and U87-R)
cells
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Discussion
TMZ, an imidazotetrazine derivative of the alkylating
agent dacarbazine, is currently standard therapy for GBM.
TMZ is well-tolerated and is therapeutically beneficial
because of its ability to methylate DNA at the N-7 or O-6
positions of guanine residues. Despite the positive effect of
TMZ on survival, treatment failure because of drug resis-
tance is a significant clinical issue. Several mechanisms
underlying TMZ resistance in GBM have been described,
including the expression of the repair enzyme O-6-
methylguanine-DNA-methyltransferase (MGMT) [19, 20],
loss of p53 function [21], selection of pre-existing TMZ-
resistant cells [3], mitochondrial adaptive response [22],
and dysregulation of glucose transporters and drug
metabolism [23]. At present, effective strategies for treat-
ment of TMZ-resistant GBM are lacking. Use of O-6-
benzylguanine (O6-BG), an inhibitor of MGMT, has been
tested in a phase II trial, with mixed outcomes [24].
GBM is characterized by poorly organized vasculature,
hypoxic areas, and necrosis. Hypoxia in tumors is generally
associated with increased aggressiveness and resistance to
chemotherapy and radiation [12]. In GBM, hypoxia is
associated with increased expression of stem-cell markers,
and formation of neurospheres and other drug-resistant
phenotypes [25]. Pastolatto et al. reported high expression
Fig. 4 Western blotting shows
upregulation of apoptotic
mediators. Activation of caspase
3 and increased Bax:Bcl-2 ratio
are positively associated with
increased oxygen saturation and
concomitant TMZ. a D54 and
b U87. HP, hyperoxia; N,
normoxia; H, hypoxia; S, TMZ-
sensitive GBM cells; R, TMZ-
resistant GBM cells
472 J Neurooncol (2012) 109:467–475
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of MGMT (a DNA repair enzyme in GBM stem cells) that
was positively correlated with intra-tumoral hypoxia and
TMZ resistance [26]. In an attempt to overcome TMZ
resistance, inhibition of hypoxia-inducible factors (HIFs), a
key regulator of cellular responses to hypoxia, has been
conceived as a therapeutic approach for enhancement of
chemosensitivity [27, 28]. Inhibitors of HIFs have been
studied as chemotherapy adjuncts with therapeutic agents,
for example angiogenesis inhibitors and cytotoxic drugs
[29, 30]. Shen et al. reported the robust anti-tumor effects
of combining HIF-1a inhibition with TMZ in D54 GBM
cells [31].
We have adopted a different approach to modulation
of hypoxia-mediated chemoresistance—use of induced
hyperoxia. Hyperoxia has previously been shown to inhibit
cell proliferation [32] and potentiate the effect of chemo-
therapy by enhancement of cytotoxicity or neovasculari-
zation in cancers [33]. Its use as a chemotherapy adjunct
has been described for a variety of conditions, for example
ovarian [15], breast [34], bone [35], prostate [36], and lung
cancers [37]. For brain tumors, hyperoxia in the form of
hyperbaric oxygen therapy (HBO) has been shown to
increase oxygen level both within and around glioma tis-
sues in patients [38]. Hyperoxia may also promote a
reversion from anaerobic metabolism to non-tumorigenic
oxidative metabolism [39]. Reported studies on HBO for
brain tumors focused mainly on its role as a radiation
sensitizer [40, 41] and in the prevention of radiation-
induced brain injury [42]. The potential use of hyerpoxia as
a chemotherapy adjunct remains unexplored. Stuhr et al.
reported reduced tumor growth, reduced vascular density,
and changes in gene expression after normobaric and
moderate HBO therapy but without concomitant TMZ [16].
As far as we are aware, ours is the first study using
hyperoxia as an adjuvant to TMZ therapy for GBM. With
an in-vitro model, we demonstrated that normobaric
hyperoxia could enhance TMZ cytotoxicity whereas
hypoxia had survival benefits. Furthermore, TMZ-resistant
cells could regain the same chemo-sensitivity toward TMZ
as their parent TMZ-sensitive cells. The potential clinical
implication is that hyperoxia may be used to attenuate
TMZ resistance in GBM. Regarding the underlying
mechanism, our findings suggested that hyperoxia-induced
apoptosis was likely to be caspase-dependent. Caspase
activation is the irreversible onset of apoptosis [43], and
several studies have also described caspase activation as
one of the crucial steps in hyperoxia-induced cell death
[44, 45]. Our study provides additional information about
this phenomenon in brain tumor cells, in that caspase 3
activation was enhanced synergistically under combined
Fig. 5 Activation of the Erk1/2
MAPK signal transduction
pathway after exposure to
hyperoxia and TMZ treatment.
Increased phosphorylation of
Erk1/2 proteins under hyperoxia
and concomitant TMZ
conditions as demonstrated by
western blotting. a D54 and
b U87
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hyperoxia–TMZ treatment. Similar changes in Bax:Bcl-2
ratio were also indicative of the importance of pro and anti-
apoptotic proteins [46].
We also demonstrated that Erk1/2 MAPK may be crit-
ically involved in regulating hyperoxia-induced cell death
[47]. The latter may be regulated by a variety of factors
[43], for example activation of the protein kinases that
participate in signal transduction [48]. Although it is gen-
erally believed to be a survival mediator for protecting
cells against cell death, Erk1/2 MAPK has been shown to
mediate hyperoxic cell death [49, 50]. In our study, the
increased phosphorylation of Erk1/2 after exposure to
concomitant hyperoxia–TMZ treatment was suggestive of
a potentiating effect on cell death. Taken together, our
findings indicate that apoptosis and MAPK pathways may
be intimately involved in a signaling network under
hyperoxia in GBM. The exact mechanism by which this
could modulate hyerpoxia-mediated and TMZ-mediated
cell death deserves further studies.
This is the first study to investigate the effect of
hyperoxia as an adjunct to TMZ in GBM. Combined
hyperoxia can significantly potentiate the anti-tumor effect
of TMZ. Hyperoxia may attenuate TMZ resistance in GBM
via MAPK signaling and apoptotic pathways. Our findings
lay the foundation for further in-vivo studies, and have
potentially important implications in the treatment of GBM
and other cancers in which chemoresistance has a major
effect on treatment outcome.
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